These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 26071795)

  • 61. Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
    Ma Y; Zhang S; Zang L; Li J; Li J; Kang Y; Ren W
    Eur J Cancer; 2016 Dec; 69():86-101. PubMed ID: 27821323
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].
    Kulka J; Tokés AM; Tóth AI; Szász AM; Farkas A; Borka K; Járay B; Székely E; Istók R; Lotz G; Madaras L; Korompay A; Harsányi L; László Z; Rusz Z; Molnár BA; Molnár IA; Kenessey I; Szentmártoni G; Székely B; Dank M
    Magy Onkol; 2009 Dec; 53(4):335-43. PubMed ID: 20071305
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
    von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
    Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.
    Toi M; Nakamura S; Kuroi K; Iwata H; Ohno S; Masuda N; Kusama M; Yamazaki K; Hisamatsu K; Sato Y; Kashiwaba M; Kaise H; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Takatsuka Y;
    Breast Cancer Res Treat; 2008 Aug; 110(3):531-9. PubMed ID: 17879158
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Neoadjuvant treatment for locally advanced breast cancer. Comparison of two schemes based on docetaxel-epirubicin vs. 5-fluorouracil-epirubicin-cyclophosphamide].
    Cortés-Flores AO; Morgan-Villela G; Castro-Cervantes JM; Vázquez-Camacho G; Fuentes-Orozco C; González-Ojeda A
    Cir Cir; 2008; 76(1):23-8. PubMed ID: 18492416
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Effects of neoadjuvant chemotherapy of docetaxel combined with and epirubicin or pirarubicin on breast cancer: clinical analysis of 160 cases].
    Li XR; Wang JD; Zhang YJ; Kong QL; Ma B; Li J; Zheng YQ; Chen YQ; Jin YC; Li R
    Zhonghua Yi Xue Za Zhi; 2009 Jan; 89(2):87-90. PubMed ID: 19489268
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy.
    Chiu JW; Leung R; Tang V; Cheuk WY; Lo J; Kwok GW; Wong H; Suen D; Cheung P; Wong TT; Yau T; Kwong A
    Postgrad Med J; 2019 Mar; 95(1121):155-161. PubMed ID: 31004045
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.
    Bria E; Furlanetto J; Carbognin L; Brunelli M; Caliolo C; Nortilli R; Massari F; Pedron S; Manfrin E; Pellini F; Bonetti F; Sperduti I; Pollini GP; Scarpa A; Tortora G
    Clin Breast Cancer; 2015 Feb; 15(1):16-23. PubMed ID: 25034441
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies.
    Okuma HS; Koizumi F; Hirakawa A; Nakatochi M; Komori O; Hashimoto J; Kodaira M; Yunokawa M; Yamamoto H; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
    Br J Cancer; 2016 Aug; 115(4):411-9. PubMed ID: 27415010
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.
    Vici P; Mottolese M; Pizzuti L; Barba M; Sperati F; Terrenato I; Di Benedetto A; Natoli C; Gamucci T; Angelucci D; Ramieri MT; Di Lauro L; Sergi D; Bartucci M; Dattilo R; Pagliuca A; De Maria R; Maugeri-Saccà M
    Oncotarget; 2014 Oct; 5(20):9619-25. PubMed ID: 25294813
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.
    Henderson SA; Muhammad Gowdh N; Purdie CA; Jordan LB; Evans A; Brunton T; Thompson AM; Vinnicombe S
    Br J Radiol; 2018 Jul; 91(1087):20180123. PubMed ID: 29641224
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).
    Charehbili A; van de Ven S; Smit VT; Meershoek-Klein Kranenbarg E; Hamdy NA; Putter H; Heijns JB; van Warmerdam LJ; Kessels L; Dercksen M; Pepels MJ; Maartense E; van Laarhoven HW; Vriens B; Wasser MN; van Leeuwen-Stok AE; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR;
    Ann Oncol; 2014 May; 25(5):998-1004. PubMed ID: 24585721
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer.
    Andrade JM; Carrara HH; Pimentel FF; Marana HR; Macchetti AH; Mouro LR; Zola FE; Tiezzi DG
    Med Oncol; 2011 Dec; 28 Suppl 1():S65-9. PubMed ID: 20953738
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
    Pivot X; Bondarenko I; Nowecki Z; Dvorkin M; Trishkina E; Ahn JH; Vinnyk Y; Im SA; Sarosiek T; Chatterjee S; Wojtukiewicz MZ; Moiseyenko V; Shparyk Y; Bello M; Semiglazov V; Song S; Lim J
    J Clin Oncol; 2018 Apr; 36(10):968-974. PubMed ID: 29373094
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Docetaxel, carboplatin plus trastuzumab as neoadjuvant setting in patients with early-stage human epidermal growth factor receptor 2 positive breast cancer: a retrospective analysis].
    Xin L; Zhang H; Zhang S; Cheng YJ; Liu Q; Xu L; Ye JM; Li T; Duan XN; Liu YH; Li ZH
    Zhonghua Wai Ke Za Zhi; 2021 Mar; 59(3):222-227. PubMed ID: 33685057
    [No Abstract]   [Full Text] [Related]  

  • 77. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.
    Rousseau C; Devillers A; Sagan C; Ferrer L; Bridji B; Campion L; Ricaud M; Bourbouloux E; Doutriaux I; Clouet M; Berton-Rigaud D; Bouriel C; Delecroix V; Garin E; Rouquette S; Resche I; Kerbrat P; Chatal JF; Campone M
    J Clin Oncol; 2006 Dec; 24(34):5366-72. PubMed ID: 17088570
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer.
    Li WP; Zhu T; Hu MX; Yang M; Ji F; Gao HF; Yang CQ; Zhang LL; Cheng MY; Xu FP; Wang K
    Neoplasma; 2020 Nov; 67(6):1409-1415. PubMed ID: 32657611
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?
    Bonnefoi H; Diebold-Berger S; Therasse P; Hamilton A; van de Vijver M; MacGrogan G; Shepherd L; Amaral N; Duval C; Drijkoningen R; Larsimont D; Piccart M
    Ann Oncol; 2003 Mar; 14(3):406-13. PubMed ID: 12598346
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Response to immunohistochemical markers' conversion after neoadjuvant chemotherapy in breast cancer patients: association between imaging and histopathologic analysis.
    Zhao Y; Wang X; Huang Y; Zhou X; Zhang D
    Clin Transl Oncol; 2020 Jan; 22(1):91-102. PubMed ID: 31006089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.